Fisher Asset Management LLC Cuts Stock Position in Sanofi $SNY

Fisher Asset Management LLC lessened its holdings in Sanofi (NASDAQ:SNY) by 4.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,578,746 shares of the company’s stock after selling 556,620 shares during the period. Fisher Asset Management LLC owned approximately 0.51% of Sanofi worth $593,717,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC lifted its holdings in shares of Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after acquiring an additional 1,869 shares during the last quarter. AQR Capital Management LLC raised its position in Sanofi by 107.2% during the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after purchasing an additional 15,791 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Sanofi by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after purchasing an additional 752 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of Sanofi by 5.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock worth $326,000 after purchasing an additional 347 shares during the period. Finally, Nisa Investment Advisors LLC increased its position in shares of Sanofi by 233.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock valued at $48,000 after purchasing an additional 700 shares during the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SNY has been the subject of several recent analyst reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. Guggenheim cut shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. Bank of America downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. Citigroup started coverage on shares of Sanofi in a research note on Tuesday, January 27th. They issued a “neutral” rating for the company. Finally, HSBC reaffirmed a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Five research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, Sanofi currently has an average rating of “Hold” and a consensus price target of $62.67.

Sanofi Trading Up 0.6%

Shares of SNY opened at $48.66 on Monday. The firm has a market capitalization of $118.68 billion, a price-to-earnings ratio of 13.52, a PEG ratio of 1.26 and a beta of 0.45. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12. The company has a 50-day moving average of $47.54 and a 200 day moving average of $48.58.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.